Methotrexate addition to phototherapy of no benefit in treating vitiligo patients

Written By :  Medha Baranwal
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2023-12-06 05:15 GMT   |   Update On 2023-12-06 06:47 GMT

Iran: A recent study published in Photodermatology, Photoimmunology and Photomedicine has shown no additional benefit of methotrexate addition compared with phototherapy alone for vitiligo treatment.The research compared oral methotrexate with phototherapy in the treatment of vitiligo in comparison with single phototherapy treatment. The findings revealed that at 6 months, both...

Login or Register to read the full article

Iran: A recent study published in Photodermatology, Photoimmunology and Photomedicine has shown no additional benefit of methotrexate addition compared with phototherapy alone for vitiligo treatment.

The research compared oral methotrexate with phototherapy in the treatment of vitiligo in comparison with single phototherapy treatment. The findings revealed that at 6 months, both treatments (methotrexate + phototherapy versus placebo + phototherapy) resulted in improvements; however, there was no significant difference in disease severity scores between the two groups at different follow-up periods.

Vitiligo is an acquired skin disease having a global prevalence of 0.5%–2% and a tendency to involve both genders. No clarity exists on the exact pathologic mechanism, but there is some evidence for the role of autoimmunity in the disease. Based on this theory, several immunosuppressive agents, such as systemic or topical corticosteroids and phototherapy (including narrowband ultraviolet B), are used.

Methotrexate is another immunosuppressant that has recently gained popularity as a single treatment for vitiligo, however, the synergistic effect and its superiority over other treatments are two crucial factors that are still obscure. Therefore, Sama Heidari, Department of Dermatology, RAZI Hospital, Tehran University of Medical Sciences, Tehran, Iran, and colleagues aimed to compare the efficacy of methotrexate+ NB-UVB versus placebo+ NB-UVB in vitiligo patients.

The double-blinded, randomized controlled trial included 42 patients with vitiligo. They were randomly allocated into two groups: the first group received three times weekly NB-UVB plus placebo, and the second group was treated with three times weekly NB-UVB in combination with a weekly dose of 12.5 mg MTX. The total treatment duration was 6 months, patients were followed up every 2 months, and the assessment tools were VIDA (disease activity indicator) and VASI (repigmentation indicator) scores.

The results demonstrated that during 6-month follow-up, both treatment groups showed improvement in VIDA and VASI scores, but found no statistical significance between the two treatment methods.

"This study demonstrated that both treatment modalities were equally effective, and there is a need for further studies to evaluate the efficacy of methotrexate with other medications with a larger sample size and longer follow-up," the researchers concluded.

Reference:

Lajevardi, V., Seyed Hosseini, Z. S., & Heidari, S. (2023). Efficacy of using oral methotrexate with phototherapy in the treatment of vitiligo in comparison with single phototherapy treatment: A double-blinded randomized controlled trial. Photodermatology, Photoimmunology & Photomedicine, 39(6), 657-662. https://doi.org/10.1111/phpp.12918


Tags:    
Article Source : Photodermatology Photoimmunology and Photomedicine

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News